Holen Sie sich die Stockscreener-App
2.65
0.38%
-0.01
Handel nachbörslich:
2.65
Schlusskurs vom Vortag:
$2.66
Offen:
$2.66
24-Stunden-Volumen:
30,186
Relative Volume:
0.10
Marktkapitalisierung:
$3.55M
Einnahmen:
$12.31M
Nettoeinkommen (Verlust:
$-5.08M
KGV:
-2.8191
EPS:
-0.94
Netto-Cashflow:
$-5.20M
1W Leistung:
-0.38%
1M Leistung:
-1.49%
6M Leistung:
-55.83%
1J Leistung:
-19.21%
1-Tages-Spanne:
$2.594
$2.6899
1-Wochen-Bereich:
$2.53
$2.85
52-Wochen-Spanne:
$2.44
$9.374
Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile
Firmenname
Sonoma Pharmaceuticals Inc
Sektor
Telefon
800-759-9305
Adresse
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Vergleichen Sie SNOA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
2.65 | 3.55M | 12.31M | -5.08M | -5.20M | -0.94 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Sonoma Pharmaceuticals Inc Aktie (SNOA) Neueste Nachrichten
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 - Marketscreener.com
Sonoma Pharmaceuticals (SNOA) to Release Quarterly Earnings on Thursday - Defense World
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results - ACCESS Newswire
Sonoma Pharmaceuticals secures new supply agreement - MSN
Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Sonoma Pharmaceuticals secures new supply agreement By Investing.com - Investing.com South Africa
Dental Market Future Business Opportunities 2025-2032 | - openPR
Hypertrophic And Keloid Scar Treatment Global Market Expected To Ascend to $12.51 Billion By 2029 - WhaTech
Sonoma Pharmaceuticals (SNOA) Stock Surges Amid Industry Decline - GuruFocus.com
Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences - ACCESS Newswire
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany - ACCESS Newswire
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea - ACCESS Newswire
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections - ACCESS Newswire
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
Sonoma County Sheriff arrests 3, seizes guns and fentanyl in drug bust - CBS San Francisco
Global Hypertrophic And Keloid Scar Treatment Market: Key - openPR
Animal Wound Care Market: Exploring Projected Size, CAGR, Key Players & Trends - openPR
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Crosses Above Two Hundred Day Moving Average – Here’s Why - Defense World
Scar Treatment Market to Surge with 10.9% CAGR, Global Revenue to Exceed US$ 8.24 Billion by 2034 - EIN News
Redhill Biopharma (NASDAQ:RDHL) Stock Quotes, Forecast and News Summary - Benzinga
Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Dental Market Set to Witness Significant Growth by 2025-2032: Sonoma Pharmaceuticals, Inc., Henry Schein, Inc, - EIN News
Scar Treatment Market Analysis: Key Drivers and Growth Projections Through 2027 - openPR
Sonoma Pharmaceuticals announces executive equity grants By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals announces executive equity grants - Investing.com India
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock - MSN
Sonoma Pharmaceuticals, Inc. Announces Two Singapore Approvals for Microcyn for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars - Marketscreener.com
Urinary Catheters Market Set to Witness Significant Growth by 2024-2031 | B. Braun SE, Coloplast Corp, BD, Cathetrix - openPR
Keloid Treatment Market Top PlayersNovartis AG, Sensus - openPR
2 Sonoma County men busted for alleged drug dealing in Marin - KRON4
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
SNOA stock touches 52-week low at $2.44 amid market challenges - Investing.com Canada
SNOA stock touches 52-week low at $2.44 amid market challenges By Investing.com - Investing.com South Africa
Bags of cocaine, gun found in Santa Rosa drug bust - KRON4
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Sonoma Pharmaceuticals (SNOA) Stock Surges Amid Market Fluctuati - GuruFocus.com
SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges - Investing.com Canada
SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices - AccessWire
Sonoma Pharmaceuticals (SNOA) Stock Declines Amid Market Activit - GuruFocus.com
Sonoma Pharmaceuticals (STU:O8Z) PE Ratio : At Loss (As of Nov. 30, 2024) - GuruFocus.com
SNOA (Sonoma Pharmaceuticals) Debt-to-Equity : 0.05 (As of Sep. 2024) - GuruFocus.com
Sonoma Pharmaceuticals (STU:O8Z) Growth Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Eye Care Product Lines - Trend Hunter
Alkermes (ALKS) Stock Surges Over 5% Amid Strong Financial Perfo - GuruFocus.com
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States - BioSpace
Sonoma Pharmaceuticals, Inc. Receives New FDA 510(K) Clearance for Microcyn(R)-Based Wound Care Hydrogel - Marketscreener.com
Scar Treatment Market Detailed In New Research Report 2024 | - openPR
Finanzdaten der Sonoma Pharmaceuticals Inc-Aktie (SNOA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):